Literature DB >> 23075863

Animal models for autoimmune liver disease--what is relevant for immune-mediated liver disease.

Matthias Hardtke-Wolenski1, Richard Taubert, Elmar Jaeckel.   

Abstract

Autoimmune hepatitis (AIH) is a chronic autoimmune inflammation of the liver usually requiring lifelong immunosuppression. Steroids and azathioprine are the standard therapy, but the therapy is accompanied by strong side effects. Due to the fact that AIH is often recognized during the late course of disease, it is difficult to obtain knowledge about the immunological mechanisms responsible for initiation of the disease. Current AIH models have been helpful for understanding and modulating liver immune responses, but are not suited to study mechanisms in chronic AIH or to develop new therapies. While most common hepatitis models are more models of injury, transgenic AIH models deal with short-term hepatitis leading to tolerance, and models with natural antigens are either self-limited or have unknown target antigens. Therefore, new models with defined onset of AIH and a standardized course of disease are essential for a better understanding of the disease and to develop new therapies.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23075863     DOI: 10.1159/000341114

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  2 in total

1.  Failure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver.

Authors:  Max Preti; Lena Schlott; David Lübbering; Daria Krzikalla; Anna-Lena Müller; Fenja A Schuran; Tobias Poch; Miriam Schakat; Sören Weidemann; Ansgar W Lohse; Christina Weiler-Normann; Marcial Sebode; Dorothee Schwinge; Christoph Schramm; Antonella Carambia; Johannes Herkel
Journal:  JCI Insight       Date:  2021-03-22

2.  Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients.

Authors:  Hongbin Li; Guoshun Li; Xinyu Zhao; Yongkang Wu; Wen Ma; Yuling Liu; Fengming Gong; Shufang Liang
Journal:  J Transl Med       Date:  2013-06-13       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.